These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 24989061)

  • 1. Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2014 Aug; 53(8):753-62. PubMed ID: 24989061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial infections.
    Pai MP; Cojutti P; Pea F
    Clin Pharmacokinet; 2015 Sep; 54(9):933-41. PubMed ID: 25850987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vancomycin dosing in children and young adults: back to the drawing board.
    Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
    Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of creatinine clearance in morbidly obese patients.
    Demirovic JA; Pai AB; Pai MP
    Am J Health Syst Pharm; 2009 Apr; 66(7):642-8. PubMed ID: 19299371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
    Pai MP; Norenberg JP; Anderson T; Goade DW; Rodvold KA; Telepak RA; Mercier RC
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2741-7. PubMed ID: 17548489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Vancomycin Prediction Methods Based on Estimated Creatinine Clearance or Trough Levels.
    Haeseker M; Croes S; Neef C; Bruggeman C; Stolk L; Verbon A
    Ther Drug Monit; 2016 Feb; 38(1):120-6. PubMed ID: 26418699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Roger C; Udy AA; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Nonobese, Obese, and Morbidly Obese Patients.
    Chung EK; Cheatham SC; Fleming MR; Healy DP; Kays MB
    J Clin Pharmacol; 2017 Mar; 57(3):356-368. PubMed ID: 27530916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population Pharmacokinetics and Pharmacodynamics of Levofloxacin in Acutely Hospitalized Older Patients with Various Degrees of Renal Function.
    Cojutti PG; Ramos-Martin V; Schiavon I; Rossi P; Baraldo M; Hope W; Pea F
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does Critical Illness Change Levofloxacin Pharmacokinetics?
    Roberts JA; Cotta MO; Cojutti P; Lugano M; Della Rocca G; Pea F
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1459-63. PubMed ID: 26666946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of levofloxacin injection in healthy Chinese volunteers and dosing regimen optimization.
    Cao G; Zhang J; Wu X; Yu J; Chen Y; Ye X; Zhu D; Zhang Y; Guo B; Shi Y
    J Clin Pharm Ther; 2013 Oct; 38(5):394-400. PubMed ID: 23701411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.
    Kirkpatrick CM; Duffull SB; Begg EJ
    Br J Clin Pharmacol; 1999 Jun; 47(6):637-43. PubMed ID: 10383541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Dosing Considerations for the Use of Linezolid in Overweight and Obese Adult Patients.
    Cojutti P; Pai MP; Pea F
    Clin Pharmacokinet; 2018 Aug; 57(8):989-1000. PubMed ID: 29080937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.
    Alobaid AS; Wallis SC; Jarrett P; Starr T; Stuart J; Lassig-Smith M; Mejia JL; Roberts MS; Sinnollareddy MG; Roger C; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6550-6557. PubMed ID: 27550344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of levofloxacin in Korean patients.
    Kiem S; Ryu SM; Lee YM; Schentag JJ; Kim YW; Kim HK; Jang HJ; Joo YD; Jin K; Shin JG; Ghim JL
    J Chemother; 2016 Aug; 28(4):308-13. PubMed ID: 25976699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosing vancomycin in the super obese: less is more.
    Crass RL; Dunn R; Hong J; Krop LC; Pai MP
    J Antimicrob Chemother; 2018 Nov; 73(11):3081-3086. PubMed ID: 30203073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized Delivery of Vancomycin by Model-Informed Bayesian Dosing Approach to Maintain an AUC24 Target in Critically Ill Patients.
    Rao Z; Guo SM; Wei YM
    Chemotherapy; 2024; 69(1):49-55. PubMed ID: 37591210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.